JP2007504194A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504194A5
JP2007504194A5 JP2006525096A JP2006525096A JP2007504194A5 JP 2007504194 A5 JP2007504194 A5 JP 2007504194A5 JP 2006525096 A JP2006525096 A JP 2006525096A JP 2006525096 A JP2006525096 A JP 2006525096A JP 2007504194 A5 JP2007504194 A5 JP 2007504194A5
Authority
JP
Japan
Prior art keywords
formulation
defibrotide
preparation
active ingredient
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006525096A
Other languages
English (en)
Japanese (ja)
Other versions
JP4671962B2 (ja
JP2007504194A (ja
Filing date
Publication date
Priority claimed from IT001714A external-priority patent/ITMI20031714A1/it
Application filed filed Critical
Publication of JP2007504194A publication Critical patent/JP2007504194A/ja
Publication of JP2007504194A5 publication Critical patent/JP2007504194A5/ja
Application granted granted Critical
Publication of JP4671962B2 publication Critical patent/JP4671962B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006525096A 2003-09-05 2004-08-27 デフィブロチド単独又は他の抗腫瘍剤との組み合わせを含む抗腫瘍製剤 Expired - Fee Related JP4671962B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001714A ITMI20031714A1 (it) 2003-09-05 2003-09-05 Formazioni ad azione antitumorale.
US53934404P 2004-01-28 2004-01-28
PCT/EP2004/009723 WO2005023273A1 (en) 2003-09-05 2004-08-27 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents

Publications (3)

Publication Number Publication Date
JP2007504194A JP2007504194A (ja) 2007-03-01
JP2007504194A5 true JP2007504194A5 (https=) 2007-06-07
JP4671962B2 JP4671962B2 (ja) 2011-04-20

Family

ID=37064585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006525096A Expired - Fee Related JP4671962B2 (ja) 2003-09-05 2004-08-27 デフィブロチド単独又は他の抗腫瘍剤との組み合わせを含む抗腫瘍製剤

Country Status (23)

Country Link
US (2) US8551967B2 (https=)
EP (1) EP1660100B1 (https=)
JP (1) JP4671962B2 (https=)
KR (1) KR20060061367A (https=)
CN (1) CN100490820C (https=)
AT (1) ATE399558T1 (https=)
AU (1) AU2004269896B2 (https=)
BR (1) BRPI0414114A (https=)
CA (1) CA2537226C (https=)
DE (1) DE602004014787D1 (https=)
DK (1) DK1660100T3 (https=)
ES (1) ES2308223T3 (https=)
IL (1) IL173785A0 (https=)
IS (1) IS8334A (https=)
IT (1) ITMI20031714A1 (https=)
MX (1) MXPA06002489A (https=)
NO (1) NO20061402L (https=)
PT (1) PT1660100E (https=)
RS (1) RS20060154A (https=)
RU (1) RU2348413C2 (https=)
UA (1) UA83500C2 (https=)
WO (1) WO2005023273A1 (https=)
ZA (1) ZA200601852B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006222045B2 (en) * 2005-03-03 2011-10-20 Gentium Spa Oligodeoxyribonucleotides of 4000-10000 Dalton for treating tumors
EP1872787A1 (en) * 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP2103689A1 (en) 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
EP2637672B1 (en) 2010-11-12 2018-08-22 Gentium S.r.l. Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd).
ES2660969T5 (es) 2012-06-22 2021-09-03 Gentium S R L Método basado en euglobulina para determinar la actividad biológica de defibrotida
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
US10380734B2 (en) * 2017-02-27 2019-08-13 Aniket Bharat Parikh System, method and computer program product for security analysis of jewelry items
TW201909904A (zh) * 2017-08-03 2019-03-16 愛爾蘭商爵士製藥愛爾蘭有限責任公司 高濃度調配物
CN112236149A (zh) 2018-04-12 2021-01-15 贾兹制药公司 用于预防和治疗细胞因子释放综合征和与免疫耗竭相关的神经毒性的去纤苷
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
EP4110287A1 (en) 2020-02-28 2023-01-04 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
TW202308659A (zh) 2021-05-06 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2154279A1 (de) 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
IT1043823B (it) 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
US3899481A (en) 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
US4853221A (en) * 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
IT1170214B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) * 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US5223609A (en) 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
IT1190313B (it) 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
US5977083A (en) 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
IT1252174B (it) 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
DE9202745U1 (de) 1992-03-02 1992-04-30 Howmedica Gmbh, 2314 Schoenkirchen Vorrichtung zum Verspannen von Wirbeln der menschlichen Wirbelsäule
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
AU754242B2 (en) * 1997-04-28 2002-11-07 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
WO1998054313A2 (en) 1997-05-30 1998-12-03 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6177545B1 (en) 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
DE19740384A1 (de) 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
WO2000074634A2 (en) * 1999-06-03 2000-12-14 Au Jessie L S Methods and compositions for modulating cell proliferation and cell death
EP1406930A4 (en) * 2000-12-29 2007-01-10 Savient Pharmaceuticals Inc "ISOLATED MOLECULES WITH SULFATED GROUPING CONTAINING EPITOPES, ANTIBODIES AGAINST SUCH EPITOPES AND USES THEREOF"
US6770753B2 (en) 2001-07-05 2004-08-03 The Trustees Of Columbia University In The City Of New York Phosphorothioate antisense heparanase oligonucleotides
WO2003027313A2 (en) 2001-09-24 2003-04-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US20050032882A1 (en) * 2002-03-06 2005-02-10 Sophie Chen Botanical extract compositions and methods of use
CA2487171A1 (en) * 2002-05-31 2003-12-11 Klinikum Der Universitat Regensburg Method for the protection of endothelial and epithelial cells during chemotherapy
WO2004003166A2 (en) * 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
CA2501719C (en) 2002-08-06 2013-02-05 Toray Industries, Inc. Remedy or preventive for kidney disease and method of diagnosing kidney disease
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
AU2006222045B2 (en) 2005-03-03 2011-10-20 Gentium Spa Oligodeoxyribonucleotides of 4000-10000 Dalton for treating tumors
EP1872787A1 (en) 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP1982722A1 (en) 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases

Similar Documents

Publication Publication Date Title
JP7025416B2 (ja) 好中球減少症を低減させるための組成物および方法
FI3788047T3 (fi) Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi
HRP20191957T1 (hr) Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba
JP2007504194A5 (https=)
WO2009127974A3 (ko) 심혈관계 질환 치료용 약제학적 제제
CY1106574T1 (el) Εξαφωσφορικη μυο-ινοσιτολη για τοπικη χρηση
WO2009039982A3 (en) Use of gip alone or in combination with dynorphin b as a therapeutic agent
JP2012521435A5 (https=)
WO2011159100A2 (ko) 항암 활성을 나타내는 약제학적 조성물
CO6280574A2 (es) Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
WO2009093264A3 (en) Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc.
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
AR061668A1 (es) Jarabes antihistaminicos, estables al almacenamiento, sin azucar
SA519410993B1 (ar) النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
ECSP077843A (es) Tratamiento o prevención del prurito
WO2015009731A3 (en) Azacyclic constrained analogs of fty720
JP2008531647A5 (https=)
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
JP2004534821A5 (https=)
RU2016101152A (ru) Терапевтические агенты для применения в профилактике и/или лечении гиперкинетических двигательных расстройств
AR037543A1 (es) Metodo para la terapia del cancer y composicion farmaceutica
JP2019524782A5 (https=)
ATE546133T1 (de) Orale dosierform mit trisubstituierten glycerin- verbindungen